AbarelixHormone TherapySafety Rating 8/10
Primary research areaAdvanced prostate cancer (withdrawn from US market 2005)
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range100 mg IM; withdrawn due to allergic reactions
AdministrationIM injection
Safety8/10 · FDA-approved (Plenaxis)
NCAA D1Banned
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Abarelix
Mechanism of action
GnRH receptor antagonist; immediate testosterone suppression without initial surge
Safety profile
Serious allergic reactions (boxed warning), QT prolongation · Approved for prostate cancer; immediate-onset allergic reaction risk led to restricted distribution
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Abarelix below your target.
Related pages